NCT04602598View on ClinicalTrials.gov

Zanubrutinib in Patients With IgG4-Related Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

February 11, 2025

Study Completion Date

April 3, 2025

Conditions
IgG4 Related Disease
Interventions
DRUG

Zanubrutinib 80 MG

Zanubrutinib 80 MG for 24 weeks

Trial Locations (1)

94304

Stanford University, Palo Alto

All Listed Sponsors
collaborator

Stanford University

OTHER

lead

Matthew C. Baker

OTHER